Discover
Visualize rapid, validated insights through real-world data.
Opportunities to advance RWE in Europe: Assessing today’s landscape and priorities for future guidance
Real-world evidence (RWE) has emerged as an important tool for global regulators, health ...
How medical device companies can use RWE to drive impact for patients: Q&A with Christian Howell, Aetion’s VP/GM of Medical Devices and Diagnostics
For medical device manufacturers, real-world data (RWD) and real-world evidence (RWE) are ...
Sourcing global real-world data to support R&D: Q&A with Ian Rentsch, VP of Growth and Strategic Partnerships, Aetion
Biopharma organizations are working to incorporate real-world evidence (RWE) throughout ...
Real-world data in the era of COVID-19: Expert perspectives on the changing data landscape
The COVID-19 pandemic has brought forth a new era of collaboration between health care ...
Applying regulatory experience in the technology space: Q&A with Lowell Schiller, Chief Legal and Regulatory Officer at Aetion
Lowell Schiller, J.D., recently joined Aetion as Chief Legal and Regulatory Officer, ...
Research spotlight: Using RWE to evaluate complications of COVID-19
While COVID-19 is primarily a respiratory disease, its impact has also been associated ...
Interim results of the RCT-DUPLICATE Project: Dr. Jessica Franklin on learnings thus far
The RCT-DUPLICATE project began in 2018 with the goal of informing the use of real-world ...
RWE Guidance Watch: NICE updates methods for health technology evaluations
With real-world evidence (RWE) growing in influence across health care, regulatory and ...
Data Synthesis Platform Available for the PHUSE Community
By Kayley Phillpott Posted On: December 7th, 2020
CNIL Recommends Against US Service Providers for Processing Health Data – What Does that Mean?
Organizations processing the personal data of EU citizens, and data from France in ...
RWE Guidance Watch: MHRA draft guidance on RCTs generating RWE to support regulatory decisions
With real-world evidence (RWE) growing in influence across health care, regulatory and ...
How can real-world data support opioid addiction research? Q&A with Dr. Jacob “Gus” Crothers of Groups Recover Together
The opioid epidemic is one of the greatest public health challenges this century, and its ...
ICPE research spotlight: Part III: Standard-setting research to advance the use of RWE
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Generating real-world evidence from chargemaster data: Q&A with Myla Maloney of Premier, Inc.
Most real-world data (RWD) sets are based on claims data, which provides useful ...
Can synthetic data help organizations respond to 'Schrems II'?
By Mike Hintze, Khaled El Emam Posted On: October 28th, 2020 Can synthetic data help ...
How can small- to mid-sized biopharma generate insights from RWD? Q&A with Michael Sanky of Optum Life Sciences
Optum, a new Aetion data collaborator, offers a robust range of real-world data (RWD) ...
Unlocking insights in RWD for market access and commercial teams: Q&A with Ki Park of Symphony Health
The integrated solutions of Symphony Health, a new Aetion data partner, extract data from ...
ICPE research spotlight: Part II: Exploring new methods for RWE research
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Ask the Accelerators: Dr. William Morice of Mayo Clinic Laboratories on RWE and COVID-19 diagnostics
Ask the Accelerators is a series highlighting the perspectives and work of organizations ...
PETs and Sharing Clinical Trial Data
Janssen’s Head of Clinical Data Standards & Transparency, Stephen Bamford, recently ...
ICPE research spotlight: Part I: Expanding real-world applications of RWE
This year at ICPE All Access, Aetion’s scientific research is represented across 15 ...
Ask the Accelerators: Dr. Nirosha Lederer on COVID-19’s implications for the future of RWE, and what we’ve learned so far
Ask the Accelerators is a series highlighting the perspectives and work of organizations ...
Three recommendations for generating regulatory-grade RWE: Considerations for the FDA on PDUFA VII
With the passage of the 21st Century Cures Act and the sixth Prescription Drug User Fee ...
Structuring epidemiology teams to maximize impact of RWE: Q&A with Dr. Nicolle Gatto
Nicolle Gatto, Ph.D., is the Senior Vice President of Scientific Research at Aetion, ...